PEP-Therapy raises €2.75 million in Series A financing to advance its lead candidate, PEP-010, into the clinic
Summary
PARIS, April 22, 2021 /PRNewswire/ -- PEP-Therapy, a biotechnology company developing cell penetrating peptides as targeted therapies for the treatment of cancers, announces it has raised a €2.75 million in a Series A financing round. The financing round is complemented by a €2.9 million grant from the French state innovation fund - Fonds Unique Interministériel (FUI) – previously received by PEP-Therapy, Institut Curie and Gustave Roussy to develop PEP-010 up to the end of Phase Ia/b clinical trials. PEP-Therapy and Institut Curie, Frances leading cancer center, have recently been granted approval from the French National Agency for Medicines and Health Products (ANSM) to start first-in-human clinical trial of PEP-010. Doorway is a Fintech platform - leader in online Equity Investing for the professional, qualified and corporate investor market - which presents a highly selected portfolio of startups and innovative SMEs validated through a thorough due diligence process based on the same criteria used by Venture Capital. Thanks to the collaboration with IR Top Consulting, which acts as financial advisor on AIM – Milan Stock Exchange, Doorway stands out as a unique alternative finance hub in Italy that can support companies from the startup phase to the listing.